LIFE SCIENCE LEADER: Ten years ago, Pete DeMuth was wrapping up his Ph.D. in biological engineering at MIT. In parallel, the lab at MIT was watering the sprout of a biotech business rooted in a simple hypothesis—the idea that precisely targeting vaccines to the right location in the body is critical for generating robust immunity against cancer.
TARGETED ONCOLOGY: Innovative findings in the field of cancer vaccines were presented at the Society for Immunotherapy of Cancer (SITC), focusing on a novel technology directing vaccines into lymph nodes.
Steinbuck MP, Cabana-Puig X, Palmer E, et al.
Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Nov 1-5, 2023
San Diego, CA
PHARMA SHOTS: Robert Connelly, CEO of Elicio Therapeutics, shared his views on the aftermath of the merger between Elicio Therapeutics & Angion Biomedica Corp. The strategic merger is instrumental to further advance Elicio’s product candidates with a focus on advancing its proprietary lymph node targeting Amphiphile (AMP) technology to develop immunotherapies.
Wainberg ZA, Pant S, Weekes CD, et al.
Presented at the American Association for Cancer Research Special Conference in Cancer Research: Pancreatic Cancer
September 27-30, 2023
PHARMA'S ALMANAC: At Elicio Therapeutics, we view real-world data and evidence (RWE) as a critical component for optimizing our drug development process –– particularly the design and execution of our AMPLIFY studies including patient selection and biomarkers of therapeutic response.
LAW 360: Clinical-stage biotechnology company Elicio Therapeutics Inc. said Monday it has chosen a longtime life sciences attorney to be its general counsel, overseeing the company's legal affairs as it continues its mission...
VANGUARDS OF HEALTH CARE PODCAST: Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.
FIERCE Biotech: Interest in developing a vaccine for Epstein-Barr virus, or EBV, has grown as the link between infection and later consequences like multiple sclerosis and cancer has become clear.